EYPT

EyePoint Pharmaceuticals Inc

Healthcare


Presented:06/13/2023
Price:$6.64
Cap:$0.23B
Current Price:$9.88
Cap:$0.53B

Presented

Date06/13/2023
Price$6.64
Market Cap$0.23B
Ent Value$0.03B
P/E RatioN/A
Book Value$2.29
Div Yield0%
Shares O/S34.30M
Ave Daily Vol890,928
Short Int20.26%

Current

Price$9.88
Market Cap$0.53B
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Publicly traded companies mentioned herein: Eyepoint Pharmaceuticals (EYPT)

Highlights

The presenter is long shares of Eyepoint Pharmaceuticals (EYPT), based on promising data and a view that shares are undervalued. The company is currently dealing with limited data from PKI inserts, but should benefit from a Phase 2B study with 160 patients in December. The presenter sees the limited data as manageable and thinks the stock could experience significant upside if they can take share of the $10B ophthalmology market.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.